Overview

Charles River offers two study platforms using humanized mouse models (NOG, NSG, and the new NCG) engrafted with CD34+ or PBMC. Our models have been characterized with known immune checkpoint inhibitors of clinical relevance to help take the next step in evaluating your compound in immuno-oncology. We have validated our patient-derived xenograft models as well as our human xenograft portfolio.

CD34+PBMC
HSC derived from umbilical cord; multiple donors in each cohort.A single cohort of animals can engraft with a single donor.
~Week 15: > 25% huCD45 blood cellsWeek 3: ~30% huCD45 blood cells
T cell focusedT cell focused
Long-term studies (no GvHD)Short-term studies due to GvHD
Number of T cells may vary with multiple donorsGvHD onset varies with donor
 Less costly approach

These models can be combined with a variety of tools to enhance your study outcomes, such as:

  • PDX Compendium
  • Flow cytometry
  • Optical imaging
  • Histopathology
  • Biomarker screening

Request Model Data